Skip to content

Advertisement

  • Erratum
  • Open Access

Erratum to: BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study

  • 1Email author,
  • 2,
  • 3,
  • 4,
  • 5,
  • 6,
  • 7,
  • 5, 8,
  • 9,
  • 7,
  • 10,
  • 11,
  • 12,
  • 13,
  • 14,
  • 15,
  • 16 and
BMC Cancer201414:720

https://doi.org/10.1186/1471-2407-14-720

©  Michallet et al.; licensee BioMed Central Ltd. 2014

  • Received: 3 September 2014
  • Accepted: 18 September 2014
  • Published:

The original article was published in BMC Cancer 2014 14:503

Correction

After publication of this Research Article [1], we noted errors in Table 1, and in the rate of thromboembolic events (page 7). Specifically, in Table 1 the percentage of female and male patients were incorrectly given as 7% and 3% respectively. The correct figures are 48.6% female and 51.4% male (please see a corrected version of Table 1 below, and the Additional file 1). The correct rate of thromboembolic events is 3.49% (originally stated as 3.55%).
Table 1

Patient demographics

Characteristic

Value

Age, mean ± SD (years)

66.49 ± 11.77

Patients with solid tumours, mean (years)

65.76

Patients with lymphoma, mean (years)

68.59

Patients with myeloma, mean (years)

70.65

Female (%)

48.6

Male (%)

51.4

Hb, mean ± SD (g/dL)

9.59 ± 0.88

sBP, mean ± SD (mmHg)

125.75 ± 14.48

dBP, mean ± SD (mmHg)

74.18 ± 9.79

Malignancies, n (%)

2310 (100)

Solid tumours, n (%)

1838 (79.57)

Lymphoma, n (%)

301 (13.03)

Myeloma, n (%)

171 (7.40)

Height, mean ± SD (cm)

166.35 ± 8.72

Weight, mean ± SD (kg)

67.46 ± 14.23

BMI, mean ± SD (kg/m2)

24.33 ± 4.62

BMI body mass index, dBP diastolic blood pressure, Hb haemoglobin, sBP systolic blood pressure, SD standard deviation.

Notes

Declarations

Authors’ Affiliations

(1)
Centre Hospitalier Lyon Sud, Lyon, France
(2)
Centre Alexis Vautrin, Vandoeuvre-les-Nancy, France
(3)
Institut Bergonie, Bordeaux, France
(4)
Centre Hospitalier de Troyes, Troyes, France
(5)
Centre Hospitalier de Carcassonne, Carcassonne, France
(6)
Centre Hospitalier de Montauban, Montauban, France
(7)
Clinique Sainte Anne, Strasbourg, France
(8)
Polyclinique Montréal, Carcassonne, France
(9)
Clinique Pasteur, Evreux, France
(10)
Clinique Rambot-Provencale, Aix en Provence, France
(11)
Centre Hospitalier d’Aix en Provence, Aix en Provence, France
(12)
Centre Hospitalier Régional Universitaire de Tours, Tours, France
(13)
Clinique du Cap d’Or, La Seyne sur Mer, France
(14)
Centre Frédéric JOLLIOT, Rouen, France
(15)
Centre Hospitalier de Montbéliard, Montbeliard, France
(16)
Laboratoire HOSPIRA France, MeudonLa Foret, France

References

  1. Michallet M, Luporsi E, Soubeyran P, Amar NA, Boulanger V, Carreiro M, Dourthe L-M, Labourey J-L, Lepille D, Maloisel F, Mouysset J-L, Nahon S, Narciso B, Nouyrigat P, Radji R, Sakek N, Albrand H: BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study. BMC Cancer. 2014, 14: 503-10.1186/1471-2407-14-503.View ArticlePubMedPubMed CentralGoogle Scholar

    2. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/720/prepub

Copyright

© Michallet et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement

BMC Cancer

ISSN: 1471-2407

Contact us